You are here

Survey: Most Rheumatologists Expect to Prescribe Biosimilar Infliximab Within 1 Year of Launch

Switching of currently treated patients is likely to be limited

Decision Resources Group, a health care research firm located in Burlington, Mass., finds that most surveyed rheumatologists in the U.S., France, and Germany expect to prescribe biosimilar infliximab within 1 year of its launch if the biosimilar is priced at a net discount of 15% to 30% compared with the price of Remicade (Janssen) and has demonstrated similar efficacy in clinical trials.

In other key findings, rheumatologists and gastroenterologists indicated that responding patients currently receiving a reference-brand tumor necrosis factor (TNF)-alpha inhibitor were unlikely to be switched to one of its biosimilars. Cross-brand switching of patients receiving a non–reference-brand TNF-alpha inhibitor to a biosimilar was even less likely.

Almost half of surveyed rheumatologists would consider treating their rheumatoid arthritis patients with a biosimilar TNF-alpha inhibitor after the failure of conventional disease-modifying antirheumatic drugs (DMARDs) ahead of branded TNF-alpha inhibitors.

Only a minority of surveyed gastroenterologists and rheumatologists were aware that pharmacy-level substitution of biosimilars will be permitted under certain circumstances in their country; only 14% of them expected to allow pharmacy-level substitution for all biologics and all patients.

Surveyed U.S. rheumatologists and gastroenterologists indicated that patient out-of-pocket costs will influence their prescribing of TNF-alpha inhibitor biosimilars; if a biosimilar costs the patient 30% less than the reference brand, physicians indicated that they expect to prescribe the biosimilar to more than twice the number of eligible patients compared with a biosimilar that costs the patient 10% less than the reference brand.

Source: BioTrends Research Group; October 7, 2014.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time